Unrecognised heart failure masquerading as gastrointestinal illness: lessons from a fatal case of adolescent dilated cardiomyopathy and implications for paediatric cardiac screening
DOI:
https://doi.org/10.66636/gmj.v1.i2.a122Keywords:
dilated cardiomyopathy, paediatric heart failure, sudden cardiac death, diagnostic delay, cardiac screening, adolescent, tachycardia, misdiagnosisAbstract
Background Dilated cardiomyopathy (DCM) is the most frequent cause of paediatric heart failure and the leading indication for cardiac transplantation in children and adolescents. Its diagnosis in acute care settings is frequently delayed by atypical, gastrointestinal-predominant presentations that closely mimic non-cardiac illness. No pathognomonic clinical features reliably distinguish paediatric heart failure from benign alimentary conditions, making heightened clinical suspicion indispensable.
Case presentation A 17-year-old male presented to the Emergency Department with epigastric pain and vomiting attributed to dietary indiscretion. An identical presentation two days earlier had been managed as food intoxication and discharged without cardiac investigation. On the index admission, examination revealed pallor, muffled heart sounds, and coarse breath sounds bilaterally. Vital signs demonstrated sinus tachycardia (heart rate 178 bpm), blood pressure 107/70 mmHg, respiratory rate 22 breaths/min, and peripheral oxygen saturation 96%. Biochemistry showed elevated transaminases (ALT 65 U/L; AST 86 U/L), hyponatraemia (131 mmol/L), hypocalcaemia (1.1 mmol/L), arterial hypoxaemia (pO₂ 28 mmHg), and a borderline metabolic acidosis. Electrocardiography prompted echocardiography, which demonstrated a severely dilated left ventricle with markedly depressed systolic function (ejection fraction 16% by Simpson’s biplane method) and functional mitral and aortic regurgitation, consistent with advanced DCM. Family history subsequently disclosed the premature cardiac death of a sibling, raising strong suspicion of a heritable cardiomyopathy. The patient was referred to a cardiology centre but died two months later, prior to device implantation.
Conclusion Epigastric pain and vomiting in an adolescent may represent the sole presenting features of advanced heart failure secondary to DCM. A systematic clinical approach — encompassing vigilant vital sign interpretation, thorough cardiorespiratory examination, and a low threshold for electrocardiography and echocardiography — is indispensable to avoiding catastrophic diagnostic delay. Population-level cardiac screening incorporating ECG and echocardiography represents a critical preventive strategy against sudden cardiac death in children and adolescents.
Keywords dilated cardiomyopathy; paediatric heart failure; sudden cardiac death; diagnostic delay; cardiac screening; adolescent; masquerading presentation; case report
References
1. Torbey AFM, Couto RGT, Grippa A, Maia EC, Miranda SA, Santos MAC, et al. Cardiomyopathy in children and adolescents in the era of precision medicine. Arq Bras Cardiol. 2024;121(9):e20230154. https://doi.org/10.36660/abc.20230154 DOI: https://doi.org/10.36660/abc.20230154
2. Kaski JP, Norrish G, Gimeno Blanes JR, Charron P, Elliott P, Tavazzi L, et al. Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Registry. Eur Heart J. 2024;45(16):1443–1454. https://doi.org/10.1093/eurheartj/ehae109 DOI: https://doi.org/10.1093/eurheartj/ehae109
3. Ware SM, Wilkinson JD, Tariq M, Schubert JA, Sridhar A, Colan SD, et al. Genetic causes of cardiomyopathy in children: first results from the Pediatric Cardiomyopathy Genes Study. J Am Heart Assoc. 2021;10(9):e017731. https://doi.org/10.1161/JAHA.120.017731 DOI: https://doi.org/10.1161/JAHA.121.020840
4. Lee TM, Hsu DT, Kantor P, Towbin JA, Ware SM, Colan SD, et al. Pediatric cardiomyopathies. Circ Res. 2017;121(7):855–873. https://doi.org/10.1161/CIRCRESAHA.116.309386 DOI: https://doi.org/10.1161/CIRCRESAHA.116.309386
5. Lipshultz SE, Law YM, Asante-Korang A, Austin ED, Dipchand AI, Everitt MD, et al. Cardiomyopathy in children: classification and diagnosis: a scientific statement from the American Heart Association. Circulation. 2019;140(1):e9–e68. https://doi.org/10.1161/CIR.0000000000000682 DOI: https://doi.org/10.1161/CIR.0000000000000682
6. Sun Q, Guo J, Zhang Y, Hu R, Liu G, Hou X, et al. Cardiomyopathy in children: a single-centre, retrospective study of genetic and clinical characteristics. BMJ Paediatr Open. 2024;8(1):e002024. https://doi.org/10.1136/bmjpo-2023-002024 DOI: https://doi.org/10.1136/bmjpo-2023-002024
7. Bogle C, Colan SD, Miyamoto SD, Choudhry S, Baez-Hernandez N, Brickler MM, et al. Treatment strategies for cardiomyopathy in children: a scientific statement from the American Heart Association. Circulation. 2023;148(2):174–195. https://doi.org/10.1161/CIR.0000000000001151 DOI: https://doi.org/10.1161/CIR.0000000000001151
8. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503–3626. https://doi.org/10.1093/eurheartj/ehad194 DOI: https://doi.org/10.1093/eurheartj/ehad194
9. Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol. 2013;62(22):2046–2072. https://doi.org/10.1016/j.jacc.2013.08.1644 DOI: https://doi.org/10.1016/j.jacc.2013.08.1644
10. Brownrigg JR, Leo V, Rose J, Low E, Richards S, Carr-White G, et al. Epidemiology of cardiomyopathies and incident heart failure in a population-based cohort study. Heart. 2022;108(17):1383–1391. https://doi.org/10.1136/heartjnl-2021-320181 DOI: https://doi.org/10.1136/heartjnl-2021-320181
11. Kübler J, Burgstahler C, Brendel JM, Gassenmaier S, Hagen F, Kläser N, et al. Cardiac MRI findings to differentiate athlete’s heart from hypertrophic, arrhythmogenic right ventricular, and dilated cardiomyopathy. Int J Cardiovasc Imaging. 2021;37(8):2501–2515. https://doi.org/10.1007/s10554-021-02280-6 DOI: https://doi.org/10.1007/s10554-021-02280-6
12. Zhang M, Zhang Y, Cao X. A new perspective on atrial tachycardia-induced cardiomyopathy: the misdiagnosis of epigastric pain in an 11-year-old girl. Radiol Case Rep. 2024;19(12):6538–6541. https://doi.org/10.1016/j.radcr.2024.09.086 DOI: https://doi.org/10.1016/j.radcr.2024.09.086
13. Cheng P, Wang G, Song Y, An Y. Novel association of LBX1 mutation with tetralogy of Fallot and hypertrophic cardiomyopathy: implications for cardiac development. Sci Rep. 2024;14(1):26179. https://doi.org/10.1038/s41598-024-77187-y DOI: https://doi.org/10.1038/s41598-024-77187-y
14. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Circulation. 2001;104(24):2996–3007. https://doi.org/10.1161/hc4901.102568 DOI: https://doi.org/10.1161/hc4901.102568
15. Andrews RE, Fenton MJ, Ridout DA, Burch M. New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United Kingdom and Ireland. Circulation. 2008;117(1):79–84. https://doi.org/10.1161/CIRCULATIONAHA.106.671735 DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.671735
16. Maddox TM, Januzzi JL, Allen LA, Breathett K, Butler J, Davis LL, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772–810. https://doi.org/10.1016/j.jacc.2020.11.022 DOI: https://doi.org/10.1016/j.jacc.2020.11.022
17. Nugent AW, Daubeney PEF, Chondros P, Carlin JB, Cheung M, Wilkinson LC, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348(17):1639–1646. https://doi.org/10.1056/NEJMoa021737 DOI: https://doi.org/10.1056/NEJMoa021737
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Miranda Shervashidze, Tamar Shervashidze , Khatia Dolidze, Teona Tabatadze, Tamta Verdzadze, Vakhtang Beridze, Megi Khabazi

This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is published open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
You are free to: share and adapt the work for any purpose, even commercially.
Conditions: provide appropriate credit to the authors and the Georgian Medical Journal (GMJ), link to the licence, and indicate if changes were made. Do not apply legal terms or technological measures that legally restrict others from doing anything the licence permits.
Licence: creativecommons.org/licenses/by/4.0 · Legal code: creativecommons.org/licenses/by/4.0/legalcode
Third-party material. Images or other content credited to a third party are not covered by CC BY 4.0; permission must be obtained from the rights holder for reuse beyond statutory exceptions.
Authors' rights. Authors retain copyright. First publication rights are granted to GMJ.
Data and code. Where provided, datasets or code may carry their own licences; please follow the licence stated in the article or repository record.




















